Results 21 to 30 of about 201,089 (265)

Impact of Parthanatos on the Increased Risk of Onset and Mortality in Male Patients With Pulmonary Hypertension

open access: yesAmerican Journal of Men's Health, 2021
There have been no studies as to whether parthanatos, a poly (adenosine diphosphate-ribose) polymerase-1 (PARP-1)-dependent and apoptosis-inducing factor (AIF)-mediated caspase-independent programmed cell death, is present in pulmonary hypertension (PH).
Zhen-Chun Lv MD   +7 more
doaj   +1 more source

Regulation of the pulmonary circulation [PDF]

open access: yesHeart, 1971
Factors regulating pressure and flow in the lungs are reviewed with particular emphasis on their role in regulating blood flow velocity and distribution within the lung capillaries. The behaviour of the pulmonary arterial, system, alveolar capillaries, and pulmonary venous system are considered individually.
openaire   +2 more sources

A Study of the Efficacy and Safety of Aerobic Exercise Training in Pulmonary Arterial Hypertension (the Saturday Study): Protocol for a Prospective, Randomized, and Controlled Trial

open access: yesFrontiers in Medicine, 2022
BackgroundPatients with pulmonary arterial hypertension (PAH) have reduced exercise capacity and poor quality of life. Exercise-based rehabilitation in PAH results in clinically relevant improvements in exercise capacity and hemodynamics.
Rong Jiang   +14 more
doaj   +1 more source

Discovery of the pulmonary circulation [PDF]

open access: yesEuropean Heart Journal, 2016
A reply to a reply: From ancient Persia (before 637 AD) to William Harvey (17th Century AD)   We read with the great interest the response of Bestett and Couto1 to our last publication on the discovery of pulmonary circulation by ancient Persians.2 The authors claimed that the credit for the discovery of the pulmonary circulation should be given to ...
Arman, Zargaran, Hamed, Arezaei
openaire   +2 more sources

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

open access: yesFrontiers in Pharmacology, 2023
Introduction: Pulmonary arterial hypertension (PAH) is a rare and progressive disease. Some patients treated with phosphodiesterase type 5 inhibitors (PDE-5is) fail to reach treatment goals. As a novel soluble guanylate cyclase agonist, riociguat acts on
Yu-Yang Liu   +11 more
doaj   +1 more source

The role of prolactin/vasoinhibins in cardiovascular diseases

open access: yesAnimal Models and Experimental Medicine, 2023
Prolactin (PRL) is a polypeptide hormone that is mainly synthesized and secreted by the lactotroph cells of the pituitary. There are two main isoforms of PRL: 23‐kDa PRL (named full‐length PRL) and vasoinhibins (including 5.6–18 kDa fragments).
Hui Zhao   +10 more
doaj   +1 more source

Prognostic Value of Follicle-Stimulating Hormone Levels in Predicting Survival in Men With Idiopathic Pulmonary Arterial Hypertension

open access: yesAmerican Journal of Men's Health, 2022
The objective of the study was to assess the association between changes in plasma follicle-stimulating hormone (FSH) and the potential effect on idiopathic pulmonary arterial hypertension (IPAH) in male patients.
Qian Wang   +5 more
doaj   +1 more source

Pulmonary circulation and ventilation [PDF]

open access: yesPostgraduate Medical Journal, 1974
Summary The pulmonary circuit receives the whole of the cardiac output, and the flow through it is governed by events in the systemic circulation. Its function is gaseous exchange, and the low resistance and high capacitance of the circuit is subservient to this function.
openaire   +2 more sources

Right heart remodeling in end-stage pulmonary arterial hypertension and the impact of treatment intensity

open access: yesFrontiers in Cardiovascular Medicine
BackgroundResearch on the limits of compensatory right heart remodeling and the effects of pulmonary artery hypertension (PAH) targeted therapies on these mechanisms is limited.MethodChest x-ray and echocardiographic data were collected from 143 deceased
Su-Gang Gong   +14 more
doaj   +1 more source

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

open access: yesCanadian Respiratory Journal, 2018
Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH).
Su-Gang Gong   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy